Chidamide reprograms AML-associated macrophages via HDAC3 inhibition to boost CD8+ T cell immunity
Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy frequently associated with relapse and therapeutic resistance. AML‑associated macrophages (AAMs) within the microenvironment play an important role in immune escape. Chidamide, a histone deacetylase (HDAC) inhibitor, has been reported to activate CD8 + T cells to exert anti-tumor effects. However, its effect on AAMs remains unclear. The present study aimed to investigate the effects of chidamide on AAMs and the underlying mechanisms. Chidamide treatment conferred an immunologically activated phenotype on AAMs, characterized by upregulated expression of antigen‑presenting molecules, pro‑inflammatory cytokines, and chemokines. Moreover, chidamide reversed the suppressive effect of AAMs on the proliferation of co‑cultured CD8⁺ T cells. In vivo, chidamide treatment significantly decreased leukemia burden and polarized AAMs towards the M1 phenotype. Mechanistically, chidamide inhibited HDAC3, leading to enhanced H3K27 acetylation. Integrated multi‑omics analysis of RNA‑seq, ATAC‑seq, and CUT&Tag‑seq revealed that chidamide upregulated FOSL2 expression, which in turn activated the TNF‑α/NF‑κB signaling pathway. FOSL2 was found to directly bind to the TNF promoter, thereby driving TNF‑α/NF‑κB activation. Collectively, our findings demonstrate that chidamide reprograms immunosuppressive AAMs into an immunologically activated phenotype via selective HDAC3 inhibition, thereby eliciting anti-leukemic activity. These findings provide a novel mechanistic rationale for chidamide-based therapy in AML.
Authors
- Yujie Zhang (ORCID: https://orcid.org/0000-0001-9108-9394)
- Ziyi Liang (ORCID: https://orcid.org/0000-0002-0354-3524)
- Rui Huang (ORCID: https://orcid.org/0000-0002-3048-2835)
- Zhili Tan
- Yuhua Li
- Xiaoning Li
- Yaling Zheng
Institutions
- Southern Medical University (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-20
- DOI
- https://doi.org/10.21203/rs.3.rs-11589394/v1
- Primary Topic
- Immune cells in cancer
- Type
- preprint
Funders
- National Natural Science Foundation of China